Peptide Association
Start Your Consultation
All peptides
MetabolicIn Clinical Trials

Retatrutide

Subcutaneous injection (weekly)
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization.

Mechanism of Action

This triple mechanism addresses obesity through complementary metabolic pathways.

Research Summary & Key Findings

Phase 2 trial (2023) showed up to 24.2% body weight reduction at 48 weeks, the largest weight loss reported for any anti-obesity medication. Significant improvements in liver fat content observed in NAFLD sub-study. Phase 3 trials (TRIUMPH program) ongoing.

Clinical Status

In Clinical Trials

Retatrutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Subcutaneous injection (weekly)

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Metabolic

Semaglutide (Ozempic/Wegovy)

FDA Approved

A glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances...

View details

Tirzepatide (Mounjaro/Zepbound)

FDA Approved

A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activat...

View details

AOD-9604

Investigational

A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine...

View details

Liraglutide (Saxenda/Victoza)

FDA Approved

A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a fatty acid side chain (C-16 palmitoyl) enabl...

View details

Start Your Consultation

Get an AI-proposed Retatrutide protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Retatrutide.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.